Extended Release Drugs Market
Market Insights on Extended Release Drugs covering sales outlook, demand forecast & up-to-date key trends
Extended Release Drugs Market By Drug Release, Distribution Channel & Region - Forecast 2022 – 2032
Extended Release Drugs Market Outlook (2022-2032)
[250 Pages Report] Sales in the extended release drugs market are expected to rise at a CAGR of 11% over the forecast period 2022-2032. Extended release drugs market is currently valued at US$ 48 Bn. Due to changes in the prescription patterns and rising acceptance of diverse dosage forms, demand for extended release drugs is anticipated to bolster in the forthcoming years.
|
Report Attribute |
Details |
|
Extended Release Drugs Market Size (2022) |
US$ 48 Bn |
|
Extended Release Drugs Market Projected Growth Rate (2022-2032) |
11% CAGR |
Conventional drugs release the active ingredient as soon as they are administered. Drug delivery systems are planned technologies that deliver the active ingredient in a controlled environment, controlling the time, rate, and area of drug release in the body. These systems have been proven to be safe and efficient.
Extended release drugs is a dosage formulation that reduces the dosage by half. There are specific regulations released by the FDA that extended release drugs need to comply with.
Growing adoption of various drug delivery systems by doctors and patients, safety and effectiveness of extended drug release, and a reduction in medical care expenditure due to extended release drugs will create a conducive environment for the growth in the market.
Let us know your requirement to get
100% FREE customization
What are the Trends Influencing Sales of Extended Release Drugs?
Compared to conventional oral drugs, extended release drugs are well-planned administration of medication. Extended release drugs control the time, area, and rate of the dosage, thereby increasing the safety and efficacy. With controlled release of the active ingredient, extended release drugs also help to reduce the frequency of dosage, resulting in easier and better acceptance by patients as well as increased bioavailability.
Further, growing demand for pediatric and geriatric extended drug release formulations, widespread acceptance of extended drug release systems, and notable changes in the prescription pattern of doctors will drive the market.
Advancing research & development, ongoing clinical trials in the pharmaceutical sector, and greater focus on the development of new and innovative therapeutics will further bolster the market for extended drug release.
What are the Limitations for Extended Release Drug Manufacturers?
The cost of extended drug release is a major roadblock for manufacturers. A single unit of extended release drugs costs double or triple the conventional oral dosage. The price of Namenda extended release drug is around US$ 494 for 7mg. This is expected to limit sales in the market.
Conventional drugs have an almost immediate impact whereas extended release drugs take a comparatively long time to make an impact as they have a slower course of action.
Side effects such as dose dumping could seriously affect health, which might hamper the growth in the market.
Dose dumping is the quick release of extended release drugs in the circulatory system and can lead to toxicity. Refusal of extended release drugs due to bad taste or swallowing difficulties is another factor that may impede demand in the forthcoming years.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat is the North America Extended Release Drug Market Outlook?
Owing to the introduction of new and innovative therapeutics and their widespread acceptance, North America holds a significant share in the global extended release drugs market. Presence of leading pharmaceutical and biopharmaceutical companies, along with increasing investments in research and development in the pharmaceutical sector will propel the growth in the North America extended release drug market.
The growing burden of chronic diseases and adoption of extended release drugs in treatment of hypertension will further underpin the demand for extended release drugs.
What are the Sales Prospects for Extended Release Drugs in Europe?
Increasing adoption of extended release drugs across countries such as Germany, the U.K., Italy and France is expected to boost the Europe extended release market over the assessment period.
Rising incidence of chronic diseases such as COPD, diabetes, and cancer has led to quicker adoption of extended release drugs. This is expected to create opportunities for extended release drug manufacturers operating in Europe.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
What is the Scope for Extended Release Drugs Market in Asia Pacific?
As per FMI, Asia Pacific is predicted to display the highest CAGR during the forecast period. The region has shown great potential in extended release drugs market due to rapid growth of the pharmaceutical industry.
Ongoing expansion of the pharmaceutical and biopharmaceutical sectors across countries including China and India is anticipated to steer sales in the Asia Pacific extended release drugs market.
Market Competition
Some of the key players in the the global extended release drugs market are Pfizer, Mallinckrodt, Actavis, Janssen Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma, Lavipharm Labs, Mylan Technologies, Noven, Aveva, Watson, Impax, and Ranbaxy.
The global extended release drug market is a highly competitive with leading companies focusing on developing novel therapeutics. Mergers and acquisitions are the go-to strategies adopted by key players to expand their product portfolios.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR 11% of from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2015-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in US$ Million, and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Countries Covered |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Extended Release Drug Market Survey
By Drug Release:
- Sustained release
- Controlled Release
By Distribution Channel:
- Hospital pharmacies
- Retail pharmacies
- Mail order pharmacies
- Drug Stores
By Region:
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
- Eastern Europe (Poland, Russia)
- Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
- Japan
- The Middle East and Africa (GCC, S. Africa, N. Africa)
Frequently Asked Questions
Due to the rapid growth of the pharmaceutical industry, especially in India and China, Asia Pacific is expected to emerge as an attractive market for extended release drugs.
Leading players present in the global extended release drug market include Pfizer, Mallinckrodt, Actavis, Janssen Pharmaceuticals, Endo Pharmaceuticals, Purdue Pharma, Lavipharm Labs, Mylan Technologies, Noven, Aveva, Watson, Impax, and Ranbaxy.
Rising demand for pediatric and geriatric extended drug release formulations, and ongoing clinical trials in the pharmaceutical sector are some trends that are expected to drive sales of extended release drugs.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Extended Release Drugs Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) & Volume (Tons) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Release
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis By Drug Release, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) & Volume (Tons) Analysis and Forecast By Drug Release, 2022-2032
5.3.1. Sustained Release
5.3.2. Controlled Release
5.4. Y-o-Y Growth Trend Analysis By Drug Release, 2017-2021
5.5. Absolute $ Opportunity Analysis By Drug Release, 2022-2032
6. Global Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Distributional Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis By Distributional Channel, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) & Volume (Tons) Analysis and Forecast By Distributional Channel, 2022-2032
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Mail Order Pharmacies
6.3.4. Drug Stores
6.4. Y-o-Y Growth Trend Analysis By Distributional Channel, 2017-2021
6.5. Absolute $ Opportunity Analysis By Distributional Channel, 2022-2032
7. Global Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) & Volume (Tons) Analysis By Region, 2017-2021
7.3. Current Market Size Value (US$ Mn) & Volume (Tons) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. East Asia
7.3.5. South Asia & Pacific
7.3.6. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021
8.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Drug Release
8.2.3. By Distributional Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Release
8.3.3. By Distributional Channel
8.4. Key Takeaways
9. Latin America Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Release
9.2.3. By Distributional Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Release
9.3.3. By Distributional Channel
9.4. Key Takeaways
10. Europe Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Drug Release
10.2.3. By Distributional Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Release
10.3.3. By Distributional Channel
10.4. Key Takeaways
11. East Asia Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.2. By Drug Release
11.2.3. By Distributional Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Release
11.3.3. By Distributional Channel
11.4. Key Takeaways
12. South Asia & Pacific Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Thailand
12.2.1.3. Indonesia
12.2.1.4. Malaysia
12.2.1.5. Singapore
12.2.1.6. Australia
12.2.1.7. New Zealand
12.2.1.8. Rest of South Asia & Pacific
12.2.2. By Drug Release
12.2.3. By Distributional Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Release
12.3.3. By Distributional Channel
12.4. Key Takeaways
13. MEA Extended Release Drugs Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) & Volume (Tons) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) & Volume (Tons) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Drug Release
13.2.3. By Distributional Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Release
13.3.3. By Distributional Channel
13.4. Key Takeaways
14. Key Countries Extended Release Drugs Market Analysis
14.1. U.S.
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Drug Release
14.1.2.2. By Distributional Channel
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Drug Release
14.2.2.2. By Distributional Channel
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Drug Release
14.3.2.2. By Distributional Channel
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Drug Release
14.4.2.2. By Distributional Channel
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Drug Release
14.5.2.2. By Distributional Channel
14.6. U.K.
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Drug Release
14.6.2.2. By Distributional Channel
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Drug Release
14.7.2.2. By Distributional Channel
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Drug Release
14.8.2.2. By Distributional Channel
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Drug Release
14.9.2.2. By Distributional Channel
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Drug Release
14.10.2.2. By Distributional Channel
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Drug Release
14.11.2.2. By Distributional Channel
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Drug Release
14.12.2.2. By Distributional Channel
14.13. India
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Drug Release
14.13.2.2. By Distributional Channel
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Drug Release
14.14.2.2. By Distributional Channel
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Drug Release
14.15.2.2. By Distributional Channel
14.16. Malaysia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Drug Release
14.16.2.2. By Distributional Channel
14.17. Singapore
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2021
14.17.2.1. By Drug Release
14.17.2.2. By Distributional Channel
14.18. Australia
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2021
14.18.2.1. By Drug Release
14.18.2.2. By Distributional Channel
14.19. New Zealand
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2021
14.19.2.1. By Drug Release
14.19.2.2. By Distributional Channel
14.20. GCC Countries
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2021
14.20.2.1. By Drug Release
14.20.2.2. By Distributional Channel
14.21. South Africa
14.21.1. Pricing Analysis
14.21.2. Market Share Analysis, 2021
14.21.2.1. By Drug Release
14.21.2.2. By Distributional Channel
14.22. Israel
14.22.1. Pricing Analysis
14.22.2. Market Share Analysis, 2021
14.22.2.1. By Drug Release
14.22.2.2. By Distributional Channel
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Drug Release
15.3.3. By Distributional Channel
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Pfizer
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.1.5.2. Product Strategy
16.1.1.5.3. Channel Strategy
16.1.2. Mallinckrodt
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.2.5.2. Product Strategy
16.1.2.5.3. Channel Strategy
16.1.3. Actavis
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.3.5.2. Product Strategy
16.1.3.5.3. Channel Strategy
16.1.4. Janssen Pharmaceuticals
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.4.5.2. Product Strategy
16.1.4.5.3. Channel Strategy
16.1.5. Endo Pharmaceuticals
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.5.5.2. Product Strategy
16.1.5.5.3. Channel Strategy
16.1.6. Purdue Pharma
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.6.5.2. Product Strategy
16.1.6.5.3. Channel Strategy
16.1.7. Lavipharm Labs
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.7.5.2. Product Strategy
16.1.7.5.3. Channel Strategy
16.1.8. Viatris
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.8.5.2. Product Strategy
16.1.8.5.3. Channel Strategy
16.1.9. Noven
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.9.5.2. Product Strategy
16.1.9.5.3. Channel Strategy
16.1.10. Aveva
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
16.1.10.5.2. Product Strategy
16.1.10.5.3. Channel Strategy
16.1.11. Watson
16.1.11.1. Overview
16.1.11.2. Product Portfolio
16.1.11.3. Profitability by Market Segments
16.1.11.4. Sales Footprint
16.1.11.5. Strategy Overview
16.1.11.5.1. Marketing Strategy
16.1.11.5.2. Product Strategy
16.1.11.5.3. Channel Strategy
16.1.12. Impax
16.1.12.1. Overview
16.1.12.2. Product Portfolio
16.1.12.3. Profitability by Market Segments
16.1.12.4. Sales Footprint
16.1.12.5. Strategy Overview
16.1.12.5.1. Marketing Strategy
16.1.12.5.2. Product Strategy
16.1.12.5.3. Channel Strategy
16.1.13. Ranbaxy
16.1.13.1. Overview
16.1.13.2. Product Portfolio
16.1.13.3. Profitability by Market Segments
16.1.13.4. Sales Footprint
16.1.13.5. Strategy Overview
16.1.13.5.1. Marketing Strategy
16.1.13.5.2. Product Strategy
16.1.13.5.3. Channel Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Extended Release Drugs Market Value (US$ Mn) Forecast by Region, 2017-2032
Table 2: Global Extended Release Drugs Market Volume (Tons) Forecast by Region, 2017-2032
Table 3: Global Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032
Table 4: Global Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032
Table 5: Global Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032
Table 6: Global Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032
Table 7: North America Extended Release Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 8: North America Extended Release Drugs Market Volume (Tons) Forecast by Country, 2017-2032
Table 9: North America Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032
Table 10: North America Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032
Table 11: North America Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032
Table 12: North America Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032
Table 13: Latin America Extended Release Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 14: Latin America Extended Release Drugs Market Volume (Tons) Forecast by Country, 2017-2032
Table 15: Latin America Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032
Table 16: Latin America Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032
Table 17: Latin America Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032
Table 18: Latin America Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032
Table 19: Europe Extended Release Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 20: Europe Extended Release Drugs Market Volume (Tons) Forecast by Country, 2017-2032
Table 21: Europe Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032
Table 22: Europe Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032
Table 23: Europe Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032
Table 24: Europe Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032
Table 25: East Asia Extended Release Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 26: East Asia Extended Release Drugs Market Volume (Tons) Forecast by Country, 2017-2032
Table 27: East Asia Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032
Table 28: East Asia Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032
Table 29: East Asia Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032
Table 30: East Asia Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032
Table 31: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 32: South Asia & Pacific Extended Release Drugs Market Volume (Tons) Forecast by Country, 2017-2032
Table 33: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032
Table 34: South Asia & Pacific Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032
Table 35: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032
Table 36: South Asia & Pacific Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032
Table 37: MEA Extended Release Drugs Market Value (US$ Mn) Forecast by Country, 2017-2032
Table 38: MEA Extended Release Drugs Market Volume (Tons) Forecast by Country, 2017-2032
Table 39: MEA Extended Release Drugs Market Value (US$ Mn) Forecast by Drug Release, 2017-2032
Table 40: MEA Extended Release Drugs Market Volume (Tons) Forecast by Drug Release, 2017-2032
Table 41: MEA Extended Release Drugs Market Value (US$ Mn) Forecast by Distributional Channel, 2017-2032
Table 42: MEA Extended Release Drugs Market Volume (Tons) Forecast by Distributional Channel, 2017-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032
Figure 2: Global Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032
Figure 3: Global Extended Release Drugs Market Value (US$ Mn) by Region, 2022-2032
Figure 4: Global Extended Release Drugs Market Value (US$ Mn) Analysis by Region, 2017-2032
Figure 5: Global Extended Release Drugs Market Volume (Tons) Analysis by Region, 2017-2032
Figure 6: Global Extended Release Drugs Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 7: Global Extended Release Drugs Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 8: Global Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032
Figure 9: Global Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032
Figure 10: Global Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032
Figure 11: Global Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032
Figure 12: Global Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032
Figure 13: Global Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032
Figure 14: Global Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032
Figure 15: Global Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032
Figure 16: Global Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032
Figure 17: Global Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032
Figure 18: Global Extended Release Drugs Market Attractiveness by Region, 2022-2032
Figure 19: North America Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032
Figure 20: North America Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032
Figure 21: North America Extended Release Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 22: North America Extended Release Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 23: North America Extended Release Drugs Market Volume (Tons) Analysis by Country, 2017-2032
Figure 24: North America Extended Release Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 25: North America Extended Release Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 26: North America Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032
Figure 27: North America Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032
Figure 28: North America Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032
Figure 29: North America Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032
Figure 30: North America Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032
Figure 31: North America Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032
Figure 32: North America Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032
Figure 33: North America Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032
Figure 34: North America Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032
Figure 35: North America Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032
Figure 36: North America Extended Release Drugs Market Attractiveness by Country, 2022-2032
Figure 37: Latin America Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032
Figure 38: Latin America Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032
Figure 39: Latin America Extended Release Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 40: Latin America Extended Release Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 41: Latin America Extended Release Drugs Market Volume (Tons) Analysis by Country, 2017-2032
Figure 42: Latin America Extended Release Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 43: Latin America Extended Release Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 44: Latin America Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032
Figure 45: Latin America Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032
Figure 46: Latin America Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032
Figure 47: Latin America Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032
Figure 48: Latin America Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032
Figure 49: Latin America Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032
Figure 50: Latin America Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032
Figure 51: Latin America Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032
Figure 52: Latin America Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032
Figure 53: Latin America Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032
Figure 54: Latin America Extended Release Drugs Market Attractiveness by Country, 2022-2032
Figure 55: Europe Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032
Figure 56: Europe Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032
Figure 57: Europe Extended Release Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 58: Europe Extended Release Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 59: Europe Extended Release Drugs Market Volume (Tons) Analysis by Country, 2017-2032
Figure 60: Europe Extended Release Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 61: Europe Extended Release Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 62: Europe Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032
Figure 63: Europe Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032
Figure 64: Europe Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032
Figure 65: Europe Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032
Figure 66: Europe Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032
Figure 67: Europe Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032
Figure 68: Europe Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032
Figure 69: Europe Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032
Figure 70: Europe Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032
Figure 71: Europe Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032
Figure 72: Europe Extended Release Drugs Market Attractiveness by Country, 2022-2032
Figure 73: East Asia Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032
Figure 74: East Asia Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032
Figure 75: East Asia Extended Release Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 76: East Asia Extended Release Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 77: East Asia Extended Release Drugs Market Volume (Tons) Analysis by Country, 2017-2032
Figure 78: East Asia Extended Release Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 79: East Asia Extended Release Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 80: East Asia Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032
Figure 81: East Asia Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032
Figure 82: East Asia Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032
Figure 83: East Asia Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032
Figure 84: East Asia Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032
Figure 85: East Asia Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032
Figure 86: East Asia Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032
Figure 87: East Asia Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032
Figure 88: East Asia Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032
Figure 89: East Asia Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032
Figure 90: East Asia Extended Release Drugs Market Attractiveness by Country, 2022-2032
Figure 91: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032
Figure 92: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032
Figure 93: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 94: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 95: South Asia & Pacific Extended Release Drugs Market Volume (Tons) Analysis by Country, 2017-2032
Figure 96: South Asia & Pacific Extended Release Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 97: South Asia & Pacific Extended Release Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 98: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032
Figure 99: South Asia & Pacific Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032
Figure 100: South Asia & Pacific Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032
Figure 101: South Asia & Pacific Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032
Figure 102: South Asia & Pacific Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032
Figure 103: South Asia & Pacific Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032
Figure 104: South Asia & Pacific Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032
Figure 105: South Asia & Pacific Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032
Figure 106: South Asia & Pacific Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032
Figure 107: South Asia & Pacific Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032
Figure 108: South Asia & Pacific Extended Release Drugs Market Attractiveness by Country, 2022-2032
Figure 109: MEA Extended Release Drugs Market Value (US$ Mn) by Drug Release, 2022-2032
Figure 110: MEA Extended Release Drugs Market Value (US$ Mn) by Distributional Channel, 2022-2032
Figure 111: MEA Extended Release Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 112: MEA Extended Release Drugs Market Value (US$ Mn) Analysis by Country, 2017-2032
Figure 113: MEA Extended Release Drugs Market Volume (Tons) Analysis by Country, 2017-2032
Figure 114: MEA Extended Release Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 115: MEA Extended Release Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 116: MEA Extended Release Drugs Market Value (US$ Mn) Analysis by Drug Release, 2017-2032
Figure 117: MEA Extended Release Drugs Market Volume (Tons) Analysis by Drug Release, 2017-2032
Figure 118: MEA Extended Release Drugs Market Value Share (%) and BPS Analysis by Drug Release, 2022-2032
Figure 119: MEA Extended Release Drugs Market Y-o-Y Growth (%) Projections by Drug Release, 2022-2032
Figure 120: MEA Extended Release Drugs Market Value (US$ Mn) Analysis by Distributional Channel, 2017-2032
Figure 121: MEA Extended Release Drugs Market Volume (Tons) Analysis by Distributional Channel, 2017-2032
Figure 122: MEA Extended Release Drugs Market Value Share (%) and BPS Analysis by Distributional Channel, 2022-2032
Figure 123: MEA Extended Release Drugs Market Y-o-Y Growth (%) Projections by Distributional Channel, 2022-2032
Figure 124: MEA Extended Release Drugs Market Attractiveness by Drug Release, 2022-2032
Figure 125: MEA Extended Release Drugs Market Attractiveness by Distributional Channel, 2022-2032
Figure 126: MEA Extended Release Drugs Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
